RJA INTER-OFFICE MEMORANDUM June 19, 1986

To: Dr. Bob Suber
From: Dr. Deborah A. Lee
Ms. Cindy Fulip

Subject: Ames results on sample H81 from Hazleton Biotechnologies, Inc.

The following results were obtained for sample H81 (Firnova
Powder 850.005):

Ã˜X S9 ACTIVATION

strain TA98 strain TA100 strain 1535 strain 1537 strain 1538
(rev/mg sample) (rev/mg sample) (rev/mg sample) (rev/mg sample) (rev/mg sample)

.350 (neg) .30 (neg) .118 (.neg) .0887 (neg) negative

10X S9 ACTIVATION

strain TA98 strain TA100 strain 1535 strain 1537 strain 1538
(rev/mg sample) (rev/mg sample) (rev/mg sample) (rev/mg sample) (rev/mg sample)

.183 (neg) .692 (neg) 1.03 (neg) 1.05 (.neg) .816 (neg)

Conclusions: The dose range tested was 0, 500, 1000, 2500, 5000, and
10000 ug in 50 ul. There was no significant increase in
reversion number with an increase in dose level for sample H81
with or without S9 activation for any of the 5 strains.

Please feel free to discuss these results with our lab.

Cindy Fulip

xc: Dr. C.K. Lee
Dr. G.T. Burger
Dr. J.R. Hayes

51833-4135